Jpmorgan Chase & CO Cabaletta Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 279,954 shares of CABA stock, worth $629,896. This represents 0.0% of its overall portfolio holdings.
Number of Shares
279,954
Previous 956,689
70.74%
Holding current value
$629,896
Previous $7.16 Million
81.54%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CABA
# of Institutions
126Shares Held
47.9MCall Options Held
202KPut Options Held
110K-
Jennison Associates LLC5.63MShares$12.7 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.76MShares$10.7 Million0.0% of portfolio
-
Fred Alger Management, LLC New York, NY4.12MShares$9.27 Million0.1% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.67MShares$8.27 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.04MShares$6.83 Million0.03% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $65.3M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...